Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 337 in MET-altered Solid Tumors
NCT03147976Phase 2Withdrawn
- Sponsor
- NantPharma
- Start
- May 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMG-337 in solid tumor, sponsored by NantPharma. Planned start May 2018; status: withdrawn.
02
Drugs
AMG-337
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03147976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147976.